Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 16, 2020 - Issue
Submit an article Journal homepage
172
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study

Ken Inada1 Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-3073-4588
ORCID Icon,
Sakiko Yamada2 Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7913-4041
ORCID Icon,
Hisashi Akiyoshi2 Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Yoshitsugu Kojima2 Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
,
Shuichi Iwashita3 Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-0057-9337
ORCID Icon &
Jun Ishigooka4 Institute of CNS Pharmacology, Tokyo, Japan
Pages 2267-2275 | Published online: 06 Oct 2020

References

  • GBD. 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.30496104
  • Rochon PA. Drug prescribing for older adults [Internet]. [updated 815, 2019; cited 512, 2020]. Available from: https://www.uptodate.com/contents/drug-prescribing-for-older-adults.
  • Citrome L, Stensbøl TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15(10):1219–1229. doi:10.1586/14737175.2015.108626926402059
  • Bruijnzeel D, Tandon R. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression. Drug Des Devel Ther. 2016;10:1641–1647.
  • Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604. doi:10.1124/jpet.114.21379324947465
  • Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614. doi:10.1124/jpet.114.21381924947464
  • Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880. doi:10.1176/appi.ajp.2015.1410127525882325
  • Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled Phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–135. doi:10.1016/j.schres.2015.01.03825682550
  • Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700. doi:10.1111/pcn.1268229774628
  • Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21.27566723
  • Kane JM, Skuban A, Hobart M, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016;174(1–3):93–98. doi:10.1016/j.schres.2016.04.01327188270
  • Forbes A, Hobart M, Ouyang J, et al. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433–441. doi:10.1093/ijnp/pyy00229415258
  • Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445–453.29582518
  • Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry. 1999;60(Suppl 8):29–41.
  • De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf. 2016;15(6):809–823. doi:10.1517/14740338.2016.116787326986209
  • Weiss C, Weiller E, Baker RA, et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol. 2018;33(5):255–260.29878915
  • Rutherford BR, Pott E, Tandler JM, et al. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014;71(12):1409–1421. doi:10.1001/jamapsychiatry.2014.131925321611
  • Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response– an evaluation of systematic reviews and meta-analyses across medicine. Gerontology. 2015;61(2):97–108.25427869

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.